首页 | 本学科首页   官方微博 | 高级检索  
     


Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment
Authors:Park Hyung Seok  Choi Ji-Yeob  Lee Mi-Jeong  Park Seho  Yeo Chang-Woo  Lee Sang Seop  Shin Jae-Gook  Park Byeong-Woo
Affiliation:Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Abstract:The aim of the study was to evaluate the association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. We evaluated the CYP2D6 genetic polymorphisms in 766 breast cancer patients. Among them, 110 patients whose samples were prospectively collected before surgery and treated with tamoxifen were included to evaluate the association between CYP2D6 and outcomes. The genotypes of CYP2D6 were categorized as extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) according to the activity score. The clinicopathologic features of 110 patients were not significantly different among the three groups except for the T-stage and nodal status. The high T-stage and axillary metastasis were more frequent in the PM group. While recurrence-free and overall survival in the PM group was poorer than the other groups, there was no significant difference between the EM and the IM group. The difference between the PM and the other groups on univariate analysis disappeared on multivariate analysis. These conflicting results suggest that the clinical value of CYP2D6 polymorphisms is still unclear and more large-sized and comprehensively designed trials are necessary.
Keywords:Breast Neoplasms   Cytochrome p-450 CYP2D6   Polymorphism   Single Nucleotide   Survival Analysis   Tamoxifen
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号